ACON Prakiraan rega marang bathi Aclarion Inc

Aclarion is advancing MRI spectroscopy through clinical partnerships and cloud-based spinal analytics. The company's expected P/E valuation illustrates its current market status, where the 0.00 indicator determines the metric's magnitude. Growth is supported by AI algorithms automating radiology, as well as the implementation of diagnostic software for chronic pain, the anticipated insurance reimbursement for which is already priced in.

ACON - Kapitalisasi marang proyeksi bathi aclarion.com ing rentang 28.04.2023 - 12.11.2026

Rincian metrik keuangan lan pasar Aclarion Corporation (ACON)

- nilai saham lan prakiraan konsensus rega:

Bagan rega Aclarion, Inc.|ACON - Target median analis

- data kapitalisasi pasar:

Biji pasar Aclarion Inc|ACON - Total Nilai Bisnis

- statistik nilai buku emiten:

Nilai Buku saben Saham Aclarion|ACON - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku aclarion.com|ACON - Gunggung Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- statistik bathi lan rasio pasar:

ACON - Asil keuangan resik|Proyeksi bathi mangsa ngarep Aclarion|ACON - Koefisien rega marang bathi|Pangali Forward P/E Aclarion Corp|ACON - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Aclarion Inc|ACON - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Aclarion|ACON - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan aclarion.com|ACON - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Aclarion

Analisis fundamental perusahaan:Aclarion, Inc.

This indicator calculates the ratio of the current share price to the expected earnings for the coming period, allowing for an assessment of the premium paid for potential business growth. By analyzing the forward P/E trend of Aclarion (ACON), a conservative investor can weigh market expectations against critical liquidity risks facing Aclarion (ACON) caused by the slow adoption of its AI platform in clinics to determine the asset's margin of safety.

Pesaing Aclarion (ACON)

Rega marang bathi mangsa ngarep Abbott (ABT)|Kapitalisasi marang proyeksi bathi Thermo Fisher Scientific Inc.|GE Healthcare Corp - Prakiraan rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep MTD (Mettler Toledo Inc)|Waters Corporation - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi bio-techne.com TECH|BRKR: Pangali Forward P/E|Prakiraan rega marang bathi Azenta Inc|Prakiraan rega marang bathi VREX|SMLR: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Butterfly Network, Inc. (BFLY)|Prakiraan rega marang bathi mesalabs.com MLAB|Pangali Forward P/E QSI (Quantum-Si Incorporated)|Nano-X Imaging (NNOX) - Rasio prakiraan rega marang bathi|Quanterix Corp - Pangali Forward P/E|MASS (908 Devices Corporation) - Rasio rega marang bathi mangsa ngarep|CV: Pangali Forward P/E|MXCT - Kapitalisasi marang proyeksi bathi|RPID (Rapid Micro Biosystems Inc.) - Pangali Forward P/E|Prakiraan rega marang bathi Seer Inc (SEER)|Pangali Forward P/E HYPR|Pangali Forward P/E FONAR Corporation Inc (FONR)|Rega marang bathi mangsa ngarep Daxor DXR|Spectral AI Inc. - Rega marang bathi mangsa ngarep|VIVS: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi AKYA (Akoya Biosciences)|THMO: Pangali Forward P/E|Rasio prakiraan rega marang bathi Talis Biomedical Corporation (TLIS)|Rega marang bathi mangsa ngarep T2 Biosystems, Inc.